Compare ACFN & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACFN | LTRN |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.2M | 46.8M |
| IPO Year | N/A | 2020 |
| Metric | ACFN | LTRN |
|---|---|---|
| Price | $18.15 | $2.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.7K | ★ 184.0K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.42 | $1.11 |
| 52 Week High | $33.00 | $5.74 |
| Indicator | ACFN | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 68.32 | 40.31 |
| Support Level | $16.32 | $2.49 |
| Resistance Level | $19.86 | $3.09 |
| Average True Range (ATR) | 0.55 | 0.35 |
| MACD | 0.23 | -0.12 |
| Stochastic Oscillator | 100.00 | 11.27 |
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. The company operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.